

Attorney Docket No.: 13257-00040 (UMD-0096)  
Inventors: Ron et al.  
Serial No.: 09/830,176  
Filing Date: April 23, 2001  
Page 3

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A composition comprising lipopolysaccharide-stimulated, transduced, spleen-derived myeloid-committed stem cells obtained from spleen in a biological carrier medium, wherein said composition is deficient of T cells.

Claim 2 (currently amended): A composition as claimed in claim 1, wherein said lipopolysaccharide-stimulated, transduced, spleen-derived myeloid committed stem cells obtained from spleen contain an exogenous nucleic acid encoding a beneficial myeloid specific protein selected from the group consisting of glucocerebrosidase, hexosaminidase A, iduronate-2-sulphatase, sphingomyelinase and arylsulfatase A.

Claim 3 (original): A composition as claimed in claim 2 wherein said exogenous nucleic acid is operably linked to a myeloid specific promoter.

Claims 4-6 (canceled).

Claim 7 (previously presented): A method for expressing exogenous nucleic acids in myeloid-committed stem cells comprising:  
a) obtaining myeloid-committed stem cells from spleen; and

Attorney Docket No.: **13257-00040 (UMD-0096)**  
Inventors: **Ron et al.**  
Serial No.: **09/830,176**  
Filing Date: **April 23, 2001**  
Page 4

b) contacting said cells with a retroviral vector containing at least one nucleic acid encoding a myeloid specific protein, under conditions whereby said vector enters cells and expresses a protein encoded by said at least one nucleic acid.

Claim 8 (original): A method as claimed in claim 7, wherein said at least one nucleic acid encoding a myeloid specific protein is operably linked to a myeloid cell specific promoter.

Claims 9-19 (canceled).